Company intelligence / Profile preview
Latigo Biotherapeutics
Thousand Oaks, California, United Stateslatigobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Latigo Biotherapeutics has reported positive Phase 1 results for its lead candidate LTG‑001—an oral selective Nav1.8 inhibitor—for acute pain. The drug was well tolerated with rapid absorption and predictable pharmacokinetics in healthy volunteers. LTG‑305, another oral Nav1.8 inhibitor targeting chronic pain, entered Phase 1 trials in late 2024 with topline results expected mid‑2025. Both candidates aim to provide effective non-opioid alternatives for acute and chronic pain without addiction risk.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (oral selective Nav1.8 inhibitors)Ion channel modulators
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Latigo Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Latigo Biotherapeutics.